Cardiovascular diabetology. Endocrinology reports最新文献

{"title":"Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis.","authors":"Arveen Shokravi, Jayant Seth, Nelson Lu, G B John Mancini","doi":"10.1186/s40842-025-00248-2","DOIUrl":"10.1186/s40842-025-00248-2","url":null,"abstract":"<p><p>BACKGROUND: Several societies recommend sodium-glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and finerenone for cardiorenal risk reduction in select populations. This updated meta-analysis assessed the impact of SGLT2i, incretin-based therapies (i.e. GLP-1RAs and tirzepatide), and finerenone on cardiorenal outcomes in established and emerging populations. Additionally, a network meta-analysis (NMA) compared the relative efficacy between treatment classes. METHODS: A systematic search of MEDLINE and CENTRAL from January 2023 to April 2025, supplemented by studies evaluated in our prior meta-analyses, identified 33 randomized controlled trials. Random-effects models were used to generate hazard ratios for outcomes including cardiovascular (CV) mortality, all-cause mortality, heart failure (HF) hospitalization/event, non-fatal myocardial infarction (MI), non-fatal stroke, and kidney composite outcomes in various subpopulations including patients with type 2 diabetes (T2D) with atherosclerotic cardiovascular disease (ASCVD) or high CV risk, chronic kidney disease (CKD), HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), HFpEF with obesity, post-MI, acute HF, and ASCVD with overweight/obesity without T2D. NMA was performed when two or more treatment classes were reported for a given outcome within a subpopulation. RESULTS: Incretin-based therapies decreased CV mortality, all-cause mortality, non-fatal MI, and kidney composite outcomes in CKD, and reduced these outcomes as well as HF hospitalization/events and non-fatal stroke in T2D with ASCVD/high CV risk. In HFpEF with obesity, incretin-based therapies reduced HF hospitalization/events. SGLT2i reduced CV mortality, all-cause mortality, HF hospitalization/events, and kidney composite outcomes in HFrEF, and reduced these outcomes as well as non-fatal MI in CKD and T2D with ASCVD/high CV risk. SGLT2i decreased HF hospitalization/events in HFpEF, and lowered HF hospitalizations in post-MI and acute HF populations. Finerenone reduced HF hospitalizations and kidney composite outcomes in diabetic CKD and reduced HF hospitalizations in HFpEF. Using placebo as the common comparator in the NMA, SGLT2i conferred significantly greater reductions in HF hospitalization/events and kidney composite outcomes compared to incretin-based therapies in T2D with ASCVD/high CV risk and CKD. CONCLUSIONS: These findings confirm the role of SGLT2i, incretin-based therapies, and finerenone in cardiorenal risk reduction across established high-risk groups, including T2D and CKD, and extend benefits to newer populations, including acute HF and post-MI for SGLT2i, and HFpEF with obesity for incretin-based therapies. Indirect NMA evidence further suggests SGLT2i may reduce HF hospitalization/events and kidney composite outcomes more than incretin-based therapies in T2D with ASCVD/high CV risk and CKD populations. </p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"11 1","pages":"37"},"PeriodicalIF":0.0,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12683810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145703759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Missed opportunities in diabetes care: unraveling therapeutic inertia and its predictors in resource-limited settings.","authors":"Dawit Alemu Lemma, Bruke Berhanu Billoro, Abenezer Duta Wolde, Belayneh Yitayew Wallie, Ejigayehu Getahun Ganamo, Fekadu Belay Ayalew, Sintayehu Samuel Lorato","doi":"10.1186/s40842-025-00250-8","DOIUrl":"10.1186/s40842-025-00250-8","url":null,"abstract":"<p><strong>Background: </strong>Therapeutic inertia the failure to intensify treatment despite persistent hyperglycemia is a major barrier to optimal management of type 2 diabetes, particularly in low-resource settings.</p><p><strong>Methods: </strong>A hospital-based cross-sectional study was conducted from June 1, 2024, to August 30, 2024. A total of 299 systematically selected patients were included. Data were collected via structured questionnaires and patient medical records. Bivariable and multivariable binary logistic regression analyses were used to identify factors associated with therapeutic inertia. Variables with a p value < 0.25 in the bivariable analysis were included in the multivariable model, and those with a p value < 0.05 were considered statistically significant.</p><p><strong>Results: </strong>Overall, 67.2% of patients experienced therapeutic inertia. Multivariable analysis identified four independent predictors: lack of health insurance reduced the likelihood of treatment intensification (AOR = 0.177; 95% CI: 0.054-0.576; p = 0.004); management by general practitioners doubled the odds of inertia compared with specialist care (AOR = 2.002; 95% CI: 1.017-3.939; p = 0.045); higher baseline fasting plasma glucose was associated with increased odds of inertia (AOR = 1.008; 95% CI: 1.003-1.013; p = 0.003); and limited availability of point-of-care HbA1c testing substantially increased the risk of inertia (AOR = 8.423; 95% CI: 1.889-37.561; p = 0.005).</p><p><strong>Conclusion: </strong>Therapeutic inertia is highly prevalent, affecting 67.2% of ambulatory patients with type 2 diabetes at NEMMCSH. This study highlights critical barriers at patient, provider, and system levels. Interventions such as expanding insurance coverage, enhancing provider training and decision support, implementing prompts for elevated glycemia, and integrating point-of-care HbA1c testing are urgently needed to reduce therapeutic inertia and improve glycemic control in resource-constrained settings.</p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"11 1","pages":"36"},"PeriodicalIF":0.0,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12673771/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145663665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in cardiovascular disease incidence according to changes in obesity status in young diabetic patients.","authors":"Do Kyeong Song, Yeon-Ah Sung, Young Sun Hong, Min-Ho Kim, Hyejin Lee","doi":"10.1186/s40842-025-00249-1","DOIUrl":"10.1186/s40842-025-00249-1","url":null,"abstract":"<p><strong>Background: </strong>The relationship between obesity and cardiovascular disease (CVD) in obese patients with young-onset diabetes remains unclear. We investigated the incidence of CVD and the impact of changes in abdominal obesity status over time among patients with young-onset diabetes.</p><p><strong>Methods: </strong>We defined young-onset diabetes as diagnosed before the age of 40. We analyzed data from 93,453 adults aged 20-39 with diabetes who underwent health screening between 2009 and 2011 and were followed up until 2021, using a customized Korean National Health Insurance Service database. Participants were categorized into four groups according to changes in abdominal obesity status: non-obese/non-obese, non-obese/abdominal obesity, abdominal obesity/non-obese, and persistent abdominal obesity. Hazard ratios (HRs) of the risk of CVD were calculated using Cox's proportional hazards model, adjusting for age, gender, smoking status, alcohol consumption, physical activity, and use of antihypertensives and lipid-lowering therapies.</p><p><strong>Results: </strong>HR for all CVD events was 1.53 (95% CI, 1.42-1.65) in those with abdominal obesity compared to non-obese individuals based on the baseline abdominal obesity status. The group with persistent abdominal obesity during the follow-up period had a higher incidence of all CVD (HR, 1.59; 95% CI, 1.42-1.77), coronary heart disease (HR, 1.56; 95% CI, 1.35-1.80), stroke (HR, 1.57; 95% CI, 1.28-1.91), and heart failure (HR, 1.69; 95% CI, 1.29-2.22) compared to the non-obese group. In participants who transitioned from abdominal obesity to a non-obese status, the incidence of hemorrhagic stroke (HR, 1.40; 95% CI, 0.80-2.44) and heart failure (HR, 0.98; 95% CI, 0.62-1.55) was not significantly higher than the group maintaining a non-obese state.</p><p><strong>Conclusions: </strong>Abdominal obesity in young adults with diabetes is associated with a higher risk of CVD. Reducing waist circumference may mitigate the risk of hemorrhagic stroke and heart failure in this population.</p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"11 1","pages":"35"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12667064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145650810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of proteinuria in diabetic patients without chronic kidney disease undergoing percutaneous coronary intervention.","authors":"Soshi Moriya, Hiroshi Iwata, Yuichi Chikata, Takehiro Funamizu, Shinichiro Doi, Takuma Koike, Keiki Abe, Ryotaro Matsuo, Hideki Wada, Ryo Naito, Manabu Ogita, Iwao Okai, Tomotaka Dohi, Takatoshi Kasai, Shinya Okazaki, Katsumi Miyauchi, Hiroyuki Daida, Tohru Minamino","doi":"10.1186/s40842-025-00243-7","DOIUrl":"10.1186/s40842-025-00243-7","url":null,"abstract":"<p><p>BACKGROUND: Diabetes mellitus (DM) and chronic kidney disease (CKD) are well-established risk factors for adverse outcomes following percutaneous coronary intervention (PCI). However, the combined impact of DM and CKD on prognosis is underexplored, and the role of proteinuria, particularly in non-CKD patients, remains inadequately addressed. This study therefore evaluates the prognostic significance of DM and CKD in post-PCI patients, with a focus on the independent impact of proteinuria. METHODS: We retrospectively analyzed 4,887 patients who underwent PCI between 2000 and 2018, categorizing them into four groups based on DM and CKD status. Cardiovascular mortality was assessed using Kaplan-Meier survival analysis and multivariate Cox proportional hazard analysis. The prognostic impact of proteinuria (≥ 0.3 g/gCr) was evaluated within each subgroup. RESULTS: Patients with both DM and CKD exhibited the highest cardiovascular mortality risk (hazard ratio [HR] 3.04, 95% confidence interval [CI] 1.82–5.05; p < 0.001). Proteinuria was an independent predictor of cardiovascular mortality, with the strongest association observed in diabetic patients without CKD (HR 6.7, 95% CI 2.7–16.8; p < 0.001). CONCLUSIONS: The coexistence of DM and CKD synergistically elevates cardiovascular mortality risk after PCI. Proteinuria, especially in diabetic patients without CKD, is a potent prognostic marker. Targeting proteinuria may offer a novel therapeutic approach to improve outcomes in this high-risk population. </p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"11 1","pages":"34"},"PeriodicalIF":0.0,"publicationDate":"2025-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12665206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Triple arm, prospective, real-world study comparing the efficacy of FDC teneligliptin + dapagliflozin to FDC sitagliptin + dapagliflozin, and FDC linagliptin + empagliflozin in Indian type 2 diabetes mellitus patients using CGM device: the Amplify-TIR study.","authors":"Suhas Erande, Mayur Agrawal, Sanjeev Gulati, Namdev Jagtap, N S Praveen Kumar, Vinod Kumar Kapoor, Sumit Bhushan, Rujuta Gadkari, Mayur Jadhav, Sanjay Choudhari, Saiprasad Patil, Hanmant Barkate","doi":"10.1186/s40842-025-00244-6","DOIUrl":"10.1186/s40842-025-00244-6","url":null,"abstract":"<p><p>INTRODUCTION: Diabetes mellitus (DM) is a chronic metabolic disorder marked by persistent hyperglycemia. While HbA1c has traditionally been used to assess glycemic control, growing evidence highlights glycemic variability (GV) and Time in Range (TIR) as more precise indicators of glucose fluctuations, which are linked to diabetic complications, especially chronic kidney disease (CKD). Emerging combination therapies targeting different pathophysiologic mechanisms of type 2 diabetes mellitus (T2DM), such as SGLT2 inhibitors and DPP-4 inhibitors, offer promise in reducing GV. OBJECTIVE: To compare the efficacy of three commonly prescribed fixed-dose combination (FDC) therapies—Teneligliptin + Dapagliflozin (Arm-A), Sitagliptin + Dapagliflozin (Arm-B), and Linagliptin + Empagliflozin (Arm-C)—in improving glycemic control and renal parameters in Indian T2DM patients using continuous glucose monitoring (CGM). METHOD: This prospective, comparative study enrolled 90 patients (30 in each arm). CGM was used to evaluate glycemic parameters including TIR, TAR, TBR, MAGE, LAGE, MPPGE, HbA1c, FPG, PPG, and renal function indicators (eGFR, serum creatinine, BUN) at baseline and study conclusion. RESULTS: All arms demonstrated significant improvements in TIR, MAGE, LAGE, HbA1c, FPG, and PPG (p<0.001). Arm-A showed a significantly superior reduction in TAR and MPPGE compared to Arm-B (p=0.029 and p=0.040, respectively) and also outperformed Arm-B in reducing FPG (p=0.042). Renal function improved comparably across arms, with a significant decline in serum creatinine noted in Arm-A. CONCLUSION: All three FDC therapies significantly improved glycemia, with the Teneligliptin + Dapagliflozin combination offering slightly superior efficacy in reducing TAR, MPPGE, and FPG. These findings support its clinical utility in reducing glycemic variability in patients with T2DM in India. Although favorable trends were observed in renal parameters, the study duration was too short to draw definitive conclusions regarding renal safety. As such, references to renal outcomes should be interpreted with caution, and further long-term studies are warranted to validate these findings. </p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"11 1","pages":"32"},"PeriodicalIF":0.0,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12648778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145608653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of cardiorespiratory fitness and muscle strength during pregnancy with metabolic health outcomes and inflammatory parameters at 1-year postpartum in women after gestational diabetes.","authors":"Dan Yedu Quansah, Amar Arhab, Jardena J Puder","doi":"10.1186/s40842-025-00240-w","DOIUrl":"10.1186/s40842-025-00240-w","url":null,"abstract":"<p><strong>Background: </strong>Women with gestational diabetes mellitus (GDM) have increased risk of insulin resistance, glucose intolerance, and low-grade systemic inflammation in the postpartum. Higher cardiorespiratory fitness (CRF) and muscular strength are associated with improved metabolic outcomes in the general population, but data in women with GDM are lacking. We investigated the longitudinal associations of CRF and muscular strength during pregnancy with glucose intolerance, insulin resistance and inflammation parameters at 1-year postpartum in women with GDM.</p><p><strong>Methods: </strong>This is a secondary analysis of the MySweetHeart trial, which included 179 women with GDM. During pregnancy, CRF was assessed using the Chester Step test, and muscular strength was measured via handgrip strength (HS) and adjusted for pre-pregnancy body mass index (BMI). At one-year postpartum, participants underwent a 75 g oral glucose tolerance test, and we calculated HOMA-IR and MATSUDA index. We calculated glucose intolerance and assessed metabolic syndrome (MetS) and c-reactive protein (CRP) at 1-year postpartum.</p><p><strong>Results: </strong>Higher CRF during pregnancy was associated with lower risk of glucose intolerance, MetS, and insulin resistance at one-year postpartum (all p ≤ 0.047). These associations were attenuated after adjusting for classical diabetes risk factors including family history of diabetes, age, ethnicity, and pre-pregnancy BMI. Higher HS during pregnancy was associated with lower CRP, HOMA-IR, higher MATSUDA index, and reduced MetS (BMI-based) at one-year postpartum, independent of classical diabetes risk factors (all p ≤ 0.035).</p><p><strong>Conclusion: </strong>In this longitudinal cohort of women with GDM, higher CRF and HS during pregnancy were protective of adverse metabolic health outcomes at 1-year postpartum. The relationship between HS and metabolic health was independent of classical diabetes risk factors.</p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"11 1","pages":"30"},"PeriodicalIF":0.0,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12642070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145592686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced age and elevated cholesterol predict diabetic neuropathy in patients with type II diabetes mellitus in Southern Ethiopia.","authors":"Fasika Merid, Habtamu Esubalew, Tamirat Gezahegn Guyo, Firdawek Getahun","doi":"10.1186/s40842-025-00241-9","DOIUrl":"10.1186/s40842-025-00241-9","url":null,"abstract":"<p><strong>Background: </strong>Diabetic neuropathy is the debilitating most common and expensive complication of diabetes that can cause significant mortality and morbidity, resulting from foot ulceration, lower extremity amputation, and pain that reduces the quality of life. The majority of type II diabetes mellitus patients continue to develop diabetic neuropathy despite optimal glycemic control, and the identification of predictors for diabetic neuropathy is important. Thus, this study aimed to determine the predictors of diabetic neuropathy in patients with type II diabetes mellitus in Ethiopia.</p><p><strong>Methods: </strong>A hospital-based retrospective longitudinal follow-up study was conducted from January 2012 to December 2021 in patients with type II diabetes. Simple random sampling was used to select study participants, and data were collected by reviewing the medical records. Stata version 14 was used for the statistical analysis. A bivariable and multivariable Cox regression analysis was performed to identify predictors of diabetic neuropathy. The goodness of the model fitness was checked via the Cox-Snell residual. A p-value less than 0.05 was used to declare the statistical significance of the variables.</p><p><strong>Results: </strong>The incidence density of diabetic neuropathy was 3.56 cases per 1,000 person months of observation, and the median time to develop diabetic neuropathy was 105 months. Advanced age (adjusted hazard ratio (AHR) 1.03 (95% CI: 1.01, 1.06)) and total cholesterol ≥ 200 mg/dl (AHR 2.52 (95% CI: 1.25, 5.09)) were statistically significant predictors of diabetic neuropathy.</p><p><strong>Conclusion: </strong>Advanced age and hypercholesterolemia were significantly associated predictors with diabetic neuropathy. Healthcare providers need to monitor cholesterol levels in order to prevent or delay diabetic neuropathy development in patients with type 2 diabetes.</p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"11 1","pages":"29"},"PeriodicalIF":0.0,"publicationDate":"2025-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12639980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145575216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiometabolic risk reduction with digital twinning in patients with type 2 diabetes.","authors":"Seyed Arsalan Seyedi, Juan P González-Rivas, Pranav Mellacheruvu, Ananya Mellacheruvu, Seyed Pedram Aledavood, Alireza Esteghamati, Jeffrey I Mechanick","doi":"10.1186/s40842-025-00242-8","DOIUrl":"10.1186/s40842-025-00242-8","url":null,"abstract":"<p><p>Digital twin (DT) technology-real-time, data-driven virtual models of individuals-offers transformative potential in managing cardiometabolic-based chronic disease (CMBCD). The novel CMBCD model configures a progression from interacting adiposity, dysglycemia, hypertension, dyslipidemia, and residual drivers to certain cardiovascular diseases (CVDs) such as atherosclerosis, heart failure, and atrial fibrillation. Insulin resistance and type 2 diabetes (T2D) are central to this cascade, requiring management tactics where DT serves as a precision-medicine tool. A systematic search across PubMed, Embase, Web of Science, Scopus, and Cochrane identified 12 eligible studies (retrospective cohort, randomized clinical trials, and frameworks) to explore the role of DT in T2D and CMBCD. Due to data duplication and lack of homogeneity, meta-analysis was not feasible, prompting this narrative synthesis. DT-guided benefits were identified across the CMBCD spectrum: (1) adiposity - body mass index reduction by 1.8 kg/m² with decreased visceral adiposity; (2) dysglycemia - hemoglobin A1c reduction as much as 1.8% with 89% achieving glycemic targets, as well as fewer medications used, time-in-range (TIR) improved 69.7% to 86.9%, and time-above-range decreased; (3) hypertension - normal blood pressure cases increased from 46.4% to 63.1% and outperforming standard care; (4) dyslipidemia - triglycerides decreased 18.8% and high density lipoprotein (HDL) increased 6.8%; (5) residual - metabolic dysfunction-associated steatotic liver disease improvements; and (6) complications - improved chronic kidney disease, retinopathy, and cataract prediction, comprehensive CVD risk reduction, and medication de-escalation. In sum, DT appears promising for comprehensive and personalized T2D care and cardiometabolic risk reduction. Broader validation in diverse populations, refined implementation strategies, and eventual systematic reviews and meta-analyses are needed.</p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"11 1","pages":"27"},"PeriodicalIF":0.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12632027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145558932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic syndrome and associated factors among benign prostatic hyperplasia patients at Jimma University Medical center, Jimma, Southwest Ethiopia.","authors":"Hundesa Emana Urgesa, Zerihun Assefa Tereffe, Tesfaye Adugna Leta, Bedasa Addisu Nasi, Segni Gemechu Hurisa","doi":"10.1186/s40842-025-00226-8","DOIUrl":"10.1186/s40842-025-00226-8","url":null,"abstract":"<p><strong>Background: </strong>Benign prostatic hyperplasia (BPH) involves the enlargement of epithelial and stromal cells of the prostate gland. Its prevalence is increasing owing in part to the rising rate of metabolic syndrome, which includes dyslipidemia, hypertension, hyperinsulinemia, and central obesity. Despite this trend, there is a paucity of data on BPH and metabolic syndrome in the Ethiopian population. This study aims to assess the prevalence and factors associated with metabolic syndrome among BPH patients in southwestern Ethiopia.</p><p><strong>Materials and methods: </strong>A hospital-based cross-sectional study was conducted with 158 BPH patients at Jimma University Medical Center (JUMC) from January 15 to April 15, 2024. Socio-demographic data were collected via a WHO stepwise questionnaire and trained nurses collected 5 ml fasting blood samples. The samples were consequently analyzed by trained laboratory technologists at JUMC.</p><p><strong>Results: </strong>The overall prevalence of metabolic syndrome among BPH patients was 38.6% (95% CI: 0.31,0.46). There were significant associations between factors such as age (AOR = 3.43, CI: 1.3, 9), residence (AOR = 3.35, CI:1.35,8.30), total cholesterol (AOR = 3.2, CI: 1.27,8.06), low LDL levels (AOR = 3.54, CI:1.08, 11.5 hyperuricemia (AOR = 3.21, CI:1.02,10.01), BMI (AOR = 3.47, CI:1.44,8.32), waist-to-hip ratio (WHR) (AOR = 5.07, CI:2.15,11.98), and metabolic syndrome.</p><p><strong>Conclusion: </strong>The prevalence of metabolic syndrome among patients with BPH is notably high. The authors recommend the need for early assessment of risk factors and timely intervention to prevent potential complications.</p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"11 1","pages":"25"},"PeriodicalIF":0.0,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12604146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145491436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and functional outcomes of the silo technique in the management of diabetic calcaneal osteomyelitis.","authors":"Nurarif Nurhashim, Ken Meng Tai, Abdul-Hadi Kafagi, Anand Pillai","doi":"10.1186/s40842-025-00238-4","DOIUrl":"10.1186/s40842-025-00238-4","url":null,"abstract":"<p><strong>Background: </strong>Partial calcanectomy is an established alternative to amputation in diabetic calcaneal osteomyelitis, with recent studies utilising adjuvant local antibiotic delivery devices to improve outcomes. The Silo technique is a novel approach involving an antibiotic-loaded hydroxyapatite calcium sulphate bioceramic (Cerament G or V) implanted into pre-drilled holes in the calcaneus.</p><p><strong>Method: </strong>This retrospective case series involved 30 patients with chronic diabetic calcaneal osteomyelitis that underwent partial calcanectomy with Cerament G or V application via the Silo technique between 2014 and 2024. Patients were further followed up on their ambulatory status via telephone consultation. Primary outcomes were infection eradication, ulcer healing, limb salvage, patient mortality and ambulatory status.</p><p><strong>Results: </strong>Infection eradication was achieved in 29 (97%) patients, ulcer healing in 27 (90%), and limb salvage in 28 (93.3%). Ulcer recurrence occurred in 8 (26.7%) patients. The all-cause mortality rate was 6.7% at 1-year and 43.3% at 5-years. With regards to ambulatory status, 6 (20.0%) patients improved their ambulatory status from baseline, 20 (66.7%) maintained their baseline ambulatory status, and 4 (13.3%) deteriorated in ambulatory status from baseline.</p><p><strong>Conclusion: </strong>The Silo technique for diabetic calcaneal osteomyelitis demonstrates promising clinical outcomes, including infection eradication, ulcer healing, ulcer recurrence, limb salvage, 1-year mortality, and mobility. Further prospective studies with larger cohorts and randomised controlled trials are warranted to validate these exploratory findings and to better understand the factors influencing both short and long-term outcomes.</p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"11 1","pages":"26"},"PeriodicalIF":0.0,"publicationDate":"2025-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12581439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145433567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}